ESN D
Alternative Names: ESN-DLatest Information Update: 24 Jul 2025
At a glance
- Originator Enveda Biosciences
- Class Anti-inflammatories; Small molecules
- Mechanism of Action GPBAR1 protein agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammatory bowel diseases
- Discontinued Immunological disorders; Inflammation
Most Recent Events
- 23 Jul 2025 Discontinued - Preclinical for Inflammation in USA (unspecified route), before July 2025 (Enveda Biosciences pipeline, July 2025)
- 23 Jul 2025 Preclinical trials in Inflammatory bowel diseases in USA (PO), before July 2025 (Enveda Biosciences pipeline, July 2025)
- 26 Dec 2022 Preclinical trials in Immunological disorders in USA (unspecified route), prior to December 2022 (Enveda Bioscience pipeline, December 2022)